Log in | Register

E-mail
Company Name

Vertex Pharmaceuticals Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer

Loading...
Vertex Pharmaceuticals Incorporated today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Officer. Ms. Wysenski has more than 30 years of experience in building commercial operations and in developing and implementing sales and marketing activities for major pharmaceutical products. Ms. Wysenski will serve as a member of Vertex's executive team, reporting directly to the company's Chairman, President and Chief Executive Officer, Matthew Emmens.

As Chief Commercial Officer for Vertex, Ms. Wysenski will have broad responsibility for sales, marketing, market research and sales operations activities as the company creates and executes commercial plans to support the potential launch of its late-stage product opportunities.

"Nancy is a seasoned professional in the commercialization of major pharmaceutical products, and I am pleased to welcome her to Vertex," said Mr. Emmens. "In my more than 10 years of working with Nancy in prior capacities, I have seen firsthand her ability to develop highly successful and motivated sales forces. As we evolve into a fully-capable pharmaceutical company, Nancy will provide key operational and commercial expertise to support the continued advancement of our future sales and marketing strategies."

"With significant near-term commercial opportunities and a broad development pipeline to fuel future commercial growth, I am excited to join Vertex at this unique time in the company's evolution," said Ms. Wysenski. "I am encouraged by Vertex's progress in planning for their entry into the hepatitis C and cystic fibrosis markets - two disease areas of significant unmet medical need where I believe Vertex has a unique opportunity to improve the lives of patients worldwide. I look forward to building a robust commercial organization in advance of the potential launch of multiple major products in the coming years."

Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer at Endo Pharmaceuticals, a 1200-person specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski was a co-founder of EMD Pharmaceuticals, Inc., the North American subsidiary of Merck KGaA, where she held various leadership positions, including the role of President and CEO from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. After earning a B.S. in Nursing from Kent State University, Ms. Wysenski joined the Veteran's Administration Medical Center in Cleveland, Ohio where she worked as a nurse from 1977 to 1984. Ms. Wysenski also holds an Executive Masters in Business Administration from Baldwin Wallace College.
Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Importance of Fundamentals

The Importance of Fundamentals

Aug 31 | Girish Malhotra, PE, President, EPCOT International

Globally, Johnson & Johnson is known for its integrity and product quality. A few years ago they handled the Tylenol situation extremely well and were commended for it. It is astounding that the year 2010 has become a nightmare for them.  

The Quality Control Unit: Invertebrates Need Not Apply

The Quality Control Unit: Invertebrates Need Not Apply

Aug 30 | The QA Pharm

The Quality Control Unit (QCU) is the only pharmaceutical function that has a job description codified in the CGMP regulations. Don’t you find this remarkable? In fact, an entire section is devoted to describing the responsibility of the QCU and how it is to operate within the organization—namely independently.        

Multimedia

Timothy Cote - Office of Orphan Products Development

Aug 13 | Root

From approving medicines to treating snake bites to Cystic Fibrosis - Dr. Tim Cote describes a special office at the FDA, designed to address needs of people with rare diseases. Timothy Cote, M.D. - Director, Office of Orphan Products Development

Charles River Labs On WuXi PharmaTech Acquisition

Charles River Labs On WuXi PharmaTech Acquisition

May 25 | Video

Charles Rivers Laboratories International Chief Officer talks about the recent WuXi PharmaTech acquisition

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Apr 27 | Video

Peter Flinn, Biogen Idec's Senior Director, Global Project Engineering talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach about the company's Large-Scale Manufacturing Technology Map Project in Research Triangle Park, North Carolina. The project won the 2010 Operational...

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

Apr 28 | Video

Juergen Martens, Ph,D. MannKind Corporation's Corporate Vice President and Chief Technical Officer talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach durng INTERPHEX2010 about the company's Technosphere Insulin Manufacturing Facility located in Danbury, Connecticut. The...